Objective: Cytology plays an important role in the diagnosis of small cell carcinoma (SCLC). Application of immunohistochemical (IHC) markers improves the accuracy and reproducibility of the diagnosis of SCLC. We report the application of insulinoma-associated protein 1 (INSM1) in the diagnosis of SCLC in cytology samples. Methods: Our pathology data system was searched for SCLC where INSM1 IHC was performed. Patients’ demographics were recorded. Cytopathology specimens were reviewed. Results: A total of 32 cases were identified. INSM1 was positive in 31 (97%) cases. Twenty-seven cases showed a strong/diffuse pattern (84%). Four cases were focally/weak positive (13%). One case was negative (3%). the sensitivity of INSM1 for recognition of SCLC was 97%. CD56 was performed in SCLC. Twenty cases were strongly/diffusely positive (87%). One case was negative (4%). The sensitivity was 96%. Conclusion: INSM1 is positive in the majority of SCLC on cytology specimens and its sensitivity is similar to that of CD56 on SCLC. This has practical implications for the diagnosis of these tumors in cytology samples.

Keywords:
Insulinoma-associated protein 1, Neuroendocrine markers, CD56, Small cell lung carcinoma, Endobronchial ultrasound
1.
Travis WD B, E, Marx A, Nicholson, A: WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, ed 4. Lyon, IARC, 2015.
2.
Maleki Z: Diagnostic issues with cytopathologic interpretation of lung neoplasms displaying high-grade basaloid or neuroendocrine morphology. Diagn Cytopathol 2011; 39: 159–167.
3.
Thunnissen E, Borczuk AC, Flieder DB, Witte B, Beasley MB, Chung JH, Dacic S, Lantuejoul S, Russell PA, den Bakker M, Botling J, Brambilla E, de Cuba E, Geisinger KR, Hiroshima K, Marchevsky AM, Minami Y, Moreira A, Nicholson AG, Yoshida A, Tsao MS, Warth A, Duhig E, Chen G, Matsuno Y, Travis WD, Butnor K, Cooper W, Mino-Kenudson M, Motoi N, Poleri C, Pelosi G, Kerr K, Aisner SC, Ishikawa Y, Buettner RH, Keino N, Yatabe Y, Noguchi M: The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis: an international reproducibility study in a demanding set of cases. J Thorac Oncol 2017; 12: 334–346.
4.
Zheng G, Ettinger DS, Maleki Z: Utility of the quantitative Ki-67 proliferation index and CD56 together in the cytologic diagnosis of small cell lung carcinoma and other lung neuroendocrine tumors. Acta Cytol 2013; 57: 281–290.
5.
Osipovich AB, Long Q, Manduchi E, Gangula R, Hipkens SB, Schneider J, Okubo T, Stoeckert CJ Jr, Takada S, Magnuson MA: Insm1 promotes endocrine cell differentiation by modulating the expression of a network of genes that includes Neurog3 and Ripply3. Development 2014; 141: 2939–2949.
6.
Rosenbaum JN, Guo Z, Baus RM, Werner H, Rehrauer WM, Lloyd RV: INSM1: a novel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am J Clin Pathol 2015; 144: 579–591.
7.
Lan MS, Russell EK, Lu J, Johnson BE, Notkins AL: IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines. Cancer Res 1993; 53: 4169–4171.
8.
Rooper LM, Sharma R, Li QK, Illei PB, Westra WH: INSM1 Demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity. Am J Surg Pathol 2017; 41: 1561–1569.
9.
Jia S, Wildner H, Birchmeier C: Insm1 controls the differentiation of pulmonary neuroendocrine cells by repressing Hes1. Dev Biol 2015; 408: 90–98.
10.
Pedersen N, Pedersen MW, Lan MS, Breslin MB, Poulsen HS: The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer. Cancer Gene Ther 2006; 13: 375–384.
11.
Robson T, Hirst DG: Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol 2003; 2003: 110–137.
12.
McColl K, Wildey G, Sakre N, Lipka MB, Behtaj M, Kresak A, Chen Y, Yang M, Velcheti V, Fu P, Dowlati A: Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. Oncotarget 2017; 8: 73745–73756.
13.
Fujino K, Motooka Y, Hassan WA, Ali Abdalla MO, Sato Y, Kudoh S, Hasegawa K, Niimori-Kita K, Kobayashi H, Kubota I, Wakimoto J, Suzuki M, Ito T: Insulinoma-associated protein 1 is a crucial regulator of neuroendocrine differentiation in lung cancer. Am J Pathol 2015; 185: 3164–3177.
14.
Doxtader EE, Mukhopadhyay S: Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens. Cancer Cytopathol 2018126: 243–252.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.